BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

News Release

BioDelivery Sciences to Report Second-Quarter 2018 Financial Results on August 9, 2018

July 24, 2018 at 4:30 PM EDT

RALEIGH, N.C., July 24, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it will report its second quarter 2018 financial results after the close of the U.S. Financial markets on Thursday, August 9, 2018. The company will host a conference call at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial In & Webcast Information:

Date: Thursday, August 9, 2018
Time: 4:30pm Eastern Time
Domestic: 800-458-4121
International: 323-794-2093
Passcode: 2839790
Replays available through August 23, 2018
Domestic: 844-512-2921
International: 412-317-6671
Conference ID:    2839790

About BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, and opioid dependence. BDSI's headquarters is in Raleigh, North Carolina. 

For more information, please visit or follow us:

Twitter: @BioDeliverySI

© 2018 BioDelivery Sciences International, Inc. All rights reserved.

Mary Coleman
Vice President, Investor & Public Relations

Monique Kosse
Managing Director
LifeSci Advisors

Primary Logo

Source: BioDelivery Sciences International, Inc.